Application of Intravitreal Bevacizumab for Circumscribed Choroidal Hemangioma
Korean J. Ophthalmol
; Korean J. Ophthalmol;: 127-131, 2009.
Article
de En
| WPRIM
| ID: wpr-180437
Bibliothèque responsable:
WPRO
ABSTRACT
We report 3 cases of circumscribed choroidal hemangioma (CCH) effectively managed with intravitreal bevacizumab. One patient (case 1) who had recurrent CCH (1.6 mm in thickness) with prior laser photocoagulation was treated with intravitreal bevacizumab alone. Two patients (case 2 and 3) who had CCH (2.4 mm and 2.2 mm in thickness, respectively) with recent visual impairment were treated with bevacizumab followed by photodynamic therapy (PDT). Ophthalmic evaluations included visual acuity, ophthalmoscopic examination, fluorescein angiography, ultrasonography, and optical coherence tomography. Patients were followed up for 6-9 months. After therapy, all patients showed improved visual acuity due to complete resorption of subretinal fluid and macular edema. Ultrasonography demonstrated a reduction of the thickness of CCH in case 1 and complete regression of the lesions in case 2 and 3. No patient showed tumor recurrence. Intravitreal bevacizumab, alone or in combination therapy with PDT, may be a useful alternative for the treatment of symptomatic CCH with subretinal fluid.
Mots clés
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Ophtalmoscopie
/
Corps vitré
/
Tumeurs de la choroïde
/
Études de suivi
/
Inhibiteurs de l'angiogenèse
/
Facteur de croissance endothéliale vasculaire de type A
/
Tomographie par cohérence optique
/
Diagnostic différentiel
/
Hémangiome
/
Injections
Type d'étude:
Diagnostic_studies
/
Observational_studies
/
Prognostic_studies
Limites du sujet:
Female
/
Humans
/
Male
langue:
En
Texte intégral:
Korean J. Ophthalmol
Année:
2009
Type:
Article